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Abstract
Bivariate meta-analysis provides a useful framework for combining information
across related studies and has been widely utilised to combine evidence from clin-
ical studies in order to evaluate treatment efficacy. Bivariate meta-analysis has also
been used to investigate surrogacy patterns between treatment effects on the sur-
rogate and the final outcome. Surrogate endpoints play an important role in drug
development when they can be used to measure treatment effect early compared to
the final clinical outcome and to predict clinical benefit or harm. The standard bivari-
ate meta-analytic approach models the observed treatment effects on the surrogate
and final outcomes jointly, at both the within-study and between-studies levels, using
a bivariate normal distribution. For binomial data a normal approximation can be
used on log odds ratio scale, however, this method may lead to biased results when
the proportions of events are close to one or zero, affecting the validation of surro-
gate endpoints. In this paper, two Bayesian meta-analytic approaches are introduced
which allow for modelling the within-study variability using binomial data directly.
The first uses independent binomial likelihoods to model the within-study variability
avoiding to approximate the observed treatment effects, however, ignores the within-
study association. The second, models the summarised events in each arm jointly
using a bivariate copula with binomial marginals. This allows the model to take into
account the within-study association through the copula dependence parameter. We
applied the methods to an illustrative example in chronic myeloid leukemia to inves-
tigate the surrogate relationship between complete cytogenetic response (CCyR) and
event-free-survival (EFS).
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1 INTRODUCTION
Bivariate meta-analytic methods provide a natural framework for synthesising evidence obtained from two outcomes. As dis-
cussed by Riley et al.1, many clinical outcomes are correlated with each other, and correlation at the individual level will lead
to correlation between treatment effects at the study level. A bivariate random effects meta-analysis model (BRMA)2 can be
used to perform bivariate meta-analysis of correlated and normally distributed treatment effects on two outcomes. This method
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models treatment effects on both outcomes jointly with a bivariate normal distribution. When this approach is applied to bino-
mial data the proportions of events in each arm across outcomes are are transformed to obtain treatment effects on log odds ratio
scale which are assumed to be approximately normally distributed. A very popular form of the bivariate normal meta-analytic
method has been described by Houwelingen et al.2 and Riley et al.3. This approach can be easily implemented in the Bayesian
framework and used to obtain pooled effects on both outcomes whilst taking into account of the correlation between them, as
well as, to assess the study level association between the true treatment effects between the first and the second outcome4,5.
However, when modelling binomial data on log OR scale, the assumption of normality may not be reasonable. Hamza et al.6
showed that the normal approximation, used for binomial data in univariate meta-analysis leads to biased results, especially
when the proportions of events are very close to zero or one and the variance is large.
In this paper, we investigate modelling bivariate binomial data in a meta-analytic framework in the context of surrogate
endpoint evaluation. Bivariate meta-analysis of treatment effects on a surrogate and a final outcome allows for the study level
validation of a surrogate endpoint. Surrogate endpoints are becoming increasingly popular nowadays as they play a very impor-
tant role in drug development process. New advances in science have led to discovering of promising therapies which often
are targeted to specific patient populations, for example defined by a genetic biomarker. This resulted in modern clinical tri-
als carried out in smaller samples of population, whilst the increased effectiveness of these therapies led to reduced number of
events (such as deaths in cancer patients). Consequently measurement of treatment effect on overall survival (OS) requires very
long follow up time, otherwise its estimate is obtained with large uncertainty. Therefore, surrogate endpoints allowing the mea-
surement of treatment effect with higher precision at earlier follow up time compared to the final clinical outcome have been
investigated to accelerate the availability of these treatments to the patients7.
A standard way to validate the study level surrogacy is to perform a form of bivariate meta-analysis, such as BRMA, to model
jointly correlated and normally distributed treatment effects on surrogate and final outcomes2,8 and monitor the between-studies
correlation parameter. However as explained above, this approach may be problematic for binary outcomes. We proposed two
random effect meta-analytic methods for the evaluation of study level surrogate relationships of the treatment effects on binomial
outcomes, using exact likelihood approach based on the binomial distribution when modelling within-study variability. The first
approach uses the exact independent binomial likelihoods across outcomes to model the within-study variability, however it
ignores potential within-study associations. In a previous work, Riley et al.9 highlighted the importance of taking into account
the within-study correlation when BRMA model is used. To take into account the within-study association, we have developed
another method which models the summarised events on each outcome jointly using a bivariate copula with binomial marginal
distributions. This model takes into account the within-study association between the summarised events on the surrogate and the
final outcome through the copula dependence parameter. This makes the copula model a more appropriate approach as the events
on the surrogate endpoint and the final outcome are obtained from the same patients and therefore, they are correlated. Copulas
have been previously used to model individual level surrogacy patterns modelling dependencies between, for example, time to
event surrogate and final outcomes in individual patient data (IPD) based methods10. IPD, however, are often not available, and
only study level surrogacy can be validated using summary data. Thus robust methods for the synthesis of aggregate data for
surrogate endpoint evaluation are very important.
We investigate the impact of assumptions made when modelling the within-study variability on the results of the between-
studies parameters on two binomial outcomes (surrogate and final) and in particular when the proportions of events (such
as responses to treatment or deaths) are close to zero or one. We carry out this investigation in a simulation study as well
as by applying the methods (the standard BRMA model using log OR scale and the two proposed models) to an illustrative
example in chronic myeloid leukemia (CML). CML is a myeloproliferative neoplasm of hematipoietic stem cells associated
with a characteristic chromosomal translocation called the Philadelphia chromosome11. The main characteristic of CML is
that it is regarded as a slow progressive disease12. Before the molecular pathogenesis of the disease was well understood, the
median survival was 6 years, with a predicted 5-year overall survival (OS) of 47.2%13. However, the introduction of tyrosine
kinase inhibitor (TKI) therapies14 have led to dramatically improved patients outcomes with high rates of complete cytogenetic
response (CCYR) at 12 months and very few events at 2-year OS and event-free survival (EFS)15. By applying the proposed
methods we aim to assess the whether CCYR at 12 months can be considered as a valid surrogate endpoint for event free survival
(EFS) at 24months.
We describe all methods in detail in Section 2. Section 3 presents the simulation study and its results. In Section 4 we discuss
the application of the methods to the illustrative example. The paper concludes with a discussion in Section 5.
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2 METHODS
2.1 Bivariate random effects meta-analysis (BRMA)
The BRMA model for correlated and normally distributed treatment effects on two outcomes 푌1푖 and 푌2푖 was firstly intro-
duced by McIntosh16 and since then many extensions have been proposed. It is usually presented in the form described by van
Houwelingen et al.2 and Riley et al.3: (
푌1푖
푌2푖
)
∼ 푁
((
훿1푖
훿2푖
)
,
(
휎21푖 휎1푖휎2푖휌푤푖
휎1푖휎2푖휌푤푖 휎22푖
))
(1)(
훿1푖
훿2푖
)
∼ 푁
((
푑1
푑2
)
,
(
휏21 휏1휏2휌푏
휏1휏2휌푏 휏22
))
(2)
In this model, the treatment effects on the first and the second outcome 푌1푖, 푌2푖, which can be log odds ratios, are assumed to
estimate the correlated true treatment effects 훿1푖 and 훿2푖 with corresponding within-study variances 휎21푖 and 휎22푖 of the estimatesand thewithin-study correlation 휌푤푖 between them. In this hierarchical framework, these true study-level effects follow a bivariate
normal distribution with means (푑1, 푑2) corresponding to the two outcomes between-studies variances 휏21 and 휏22 and a between-studies correlation 휌푏. In the context of surrogate endpoints the between-studies correlation 휌푏 is the main parameter of interest
and it is used to assess the study level association between the treatment effect on the surrogate endpoint and the effect on the
final outcome. Equation (1) represents the within-study model and (2) is the between-studies model.
The elements of the within-study covariance matrix, 휎21푖, 휎22푖 and 휌푤푖 are assumed to be known. Whilst the estimates of thevariances are easily obtained by taking the square of the standard error for each outcome, the estimates of the within-study
correlations between the treatment effects on the two outcomes are more difficult to obtain as they would not be reported in the
original articles. When IPD are available, the correlation can be obtained by bootstrapping8 (see details in the section A.1 of
the supplementary material) or alternatively by fitting a regression model for the two outcomes with correlated errors17. Other
methods of estimating the within-study correlations have been discussed elsewhere and are summarized in Bujkiewicz et al4.
Implementing the model in the Bayesian framework the unknown parameters 휏21 , 휏22 , 푑1, 푑2 and 휌푏 have to be estimated andtherefore, prior distributions should be specified on them. For instance, the following prior distributions can be placed on the
these parameters: 훽1,2 ∼ 푁(0, 102), 휏1,2 ∼ 푈 (0, 2), to implement the natural constrain of −1 ≤ 휌푏 ≤ 1 we used the Fisher’s 푧
transformation as, 휌푏 = 푡푎푛ℎ(푧) , 푧 ∼ 푁(0, 1).
When this model is applied to binomial data (summarised events), they are transformed to obtain treatment effects on the
log OR scale: 푌1푖 = 푙표푔( 푟1퐵푖푁퐵푖−푟1퐵푖 ) − 푙표푔(
푟1퐴푖
푁퐴푖−푟1퐴푖
), 푌2푖 = 푙표푔( 푟2퐵푖푁퐵푖−푟2퐵푖 ) − 푙표푔(
푟2퐴푖
푁퐴푖−푟2퐴푖
) with corresponding the variances: 휎21푖 =
1
푟1퐵푖
+ 1
푁퐵푖−푟1퐵푖
+ 1
푟1퐴푖
+ 1
푁퐴푖−푟1퐴푖
and 휎22푖 = 1푟2퐵푖 +
1
푁퐵푖−푟2퐵푖
+ 1
푟2퐴푖
+ 1
푁퐴푖−푟2퐴푖
. Where 푟1퐴푖, 푟2퐴푖, 푟1퐵푖, 푟2퐵푖 are the number of events in the
control arm 퐴 and treatment arm 퐵 on both outcomes in study 푖 whereas,푁퐴푖 and푁퐵푖 are the arm sizes in study 푖. A modelling
issue occurs when there are no events in either of the treatment arms as the log odds ratios (푌1푖, 푌1푖) and their variances cannot
be defined. A very simple way to tackle this problem is to apply a correction, for instances, by adding 0.5. However, in some
situations the effect of adding 0.5 may lead to biased results18,19. Furthermore, when the proportions of events are close to zero
or one the assumption of normality of log ORs is unreasonable and can lead to biased results6.
2.2 Bivariate random effect meta-analysis with independent Binomials (BRMA-IB)
In this section, we introduce a bivariate meta-analytic model with independent binomial likelihoods for the first and the sec-
ond outcomes at the within-study level. This is very similar to a standard model for meta-analysis of diagnostic test accuracy
studies (where true positive and true negative observations are not correlated within a study as they are obtained from differ-
ent patients20). We assume that the number of events 푟1퐴푖, 푟2퐴푖, in the control arm 퐴 and 푟1퐵푖, 푟2퐵푖 in the experimental arm
B, on the two outcomes (the surrogate and the final outcome respectively) follow independent Binomial distributions with the
corresponding true probabilities of events 푝1퐴푖, 푝2퐴푖, 푝1퐵푖 and 푝2퐵푖:
푟1퐴푖 ∼ 퐵푖푛(푝1퐴푖, 푁퐴푖), 푟2퐴푖 ∼ 퐵푖푛(푝2퐴푖, 푁퐴푖), 푟1퐵푖 ∼ 퐵푖푛(푝1퐵푖, 푁퐵푖), 푟2퐵푖 ∼ 퐵푖푛(푝2퐵푖, 푁퐵푖) (3)
At the between-studies level (4), the true probabilities of events are transformed using a link function 푔(⋅) (e.g. logit). 휇푗푖 are
study specific baseline effects (i.e. the log-odds for the control group 퐴 and outcome 푗 = 1, 2 in study 푖) while, 훿푗푖 are the study
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specific true treatment effects on the log OR scale for outcome 푗 = 1, 2 in study 푖.
푔(푝1퐴푖) = 휇1푖, 푔(푝1퐵푖) = 휇1푖 + 훿1푖
푔(푝2퐴푖) = 휇2푖, 푔(푝2퐵푖) = 휇2푖 + 훿2푖(
훿1푖
훿2푖
)
∼ 푁
((
푑1
푑2
)
,
(
휏21 휏1휏2휌푏
휏1휏2푖휌푏 휏22
))
(4)
Where (푑1, 푑2) are the mean effects on first and the second outcome, 휏1 and 휏2 are the between studies heterogeneity parame-
ters and 휌푏 the between-studies correlation. Similarly as in the BRMA, between-studies correlation quantifies the relationship
between the surrogate endpoint and the final outcome.
To implement the model in the Bayesian framework, we place prior distributions on unknown parameters such as, the baseline
treatment effects 휇1푖,2푖 ∼ 푁(0, 102), the mean effects 푑1,2 ∼ 푁(0, 102), the between study standard deviations 휏1,2 ∼ 푈 (0, 2) and
in order to implement the natural constrain of −1 ≤ 휌푏 ≤ 1we used the Fisher’s 푧 transformation as, 휌푏 = 푡푎푛ℎ(푧) , 푧 ∼ 푁(0, 1).
The main difference between this method and the BRMA model is the within-study level (3). Here, we model the within-
study variability using exact likelihood approach based on the binomial distribution avoiding to make the restrictive assumption
of normality. This approach does not to require continuity corrections, however, the model ignores the within-study association.
This is very restrictive as the number of events in each arm on the first and the second outcomes are obtained from the same
patients and hence are expected to be correlated.
2.3 Model with bivariate copula
In this section we propose a extension of the BRMA-IB using a copula representation to model the number of events in each
arm on the first and the second outcome jointly. Copulas is a very flexible way to model multivariate data as they account for the
dependence structure avoiding the restrictive assumption of normality. First, we introduce some background on copula models.
In section 2.3.2 a copula model with binomial margins is presented.
2.3.1 Overview of copula theory
A bivariate copula 퐶 is a bivariate cumulative function (CDF) restricted to the unit square with standard uniform marginal
distributions21,22,23.
If 퐻 is a bivariate cdf with univariate cdf margins 퐹1, 퐹2 then according to the Sklar’s theorem24 for every bivariate
distribution there exists a copula representation 퐶 such that
퐻(푥1, 푥2, 휃) = 퐶(퐹1(푥1), 퐹2(푥2), 휃) (5)
The copula 퐶 is unique if 퐹1, 퐹2 are continuous random variables; otherwise, there are many possible copulas if some of the
margins have discrete components as emphasized by Genest and Neslehova25 but all coincide on the closure of 푅푎푛(퐹1) ×
푅푎푛(퐹2) where푅푎푛(퐹 ) denotes the range of 퐹 . While the derivation of the joint density is easy for the continuous case through
partial derivatives, it is not that simple in the discrete case. In this case, the joint probability mass function (pmf) is obtained
using finite differences
ℎ(푥1, 푥2, 휃) = 퐶(퐹1(푥1), 퐹2(푥2), 휃) − 퐶(퐹1(푥1 − 1), 퐹2(푥2), 휃) (6)
− 퐶(퐹1(푥1), 퐹2(푥2 − 1), 휃) + 퐶(퐹1(푥1 − 1), 퐹2(푥2 − 1), 휃)
The key benefit of this theory is that copulas avoid the assumption of normality when modelling non-normal data and allow
the marginal distributions and the dependence structure to be estimated separately as they provide a natural way to study and
measure the dependence among random variables.
Next, we describe the set copulas we used in this paper. Archimedean copulas21 have the form,
퐶(푢1, 푢2, 휃) = 휙(휙−1(푢1, 휃) + 휙−1(푢2, 휃), 휃)
where 휙(푢, 휃) is the Laplace transform of a univariate family of distributions of positive random variables, such as 휙() and
its inverse have closed forms. We used Frank copula which is one of the most popular Archimedian copulas. It is a reflection
symmetric copula without tail dependence26. In general, a bivariate copula 퐶 is reflection symmetric if its density satisfies
푐(푢1, 푢2) = 푐(1 − 푢1, 1 − 푢2) for all 0≤ 푢1, 푢2 ≤1. Otherwise, the joint density is reflection asymmetric with more probability
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in the upper tail or the lower tail. Tail dependence is another useful copula-based measure indicating dependence in extreme
values. Frank copula is given by,
퐶퐹 (푢1, 푢2, 휃) = 휃−1푙표푔
{
1 + (푒
−푢1휃 − 1)(푒−푢2휃 − 1)
(푒−휃 − 1)
}
, 휃 ∈ (−∞,∞) ⧵ {0}.
Frank copula interpolates from the Frechet lower bound 휃 → −∞ (perfect negative dependence) to the Frechet upper bound
휃 → ∞ (perfect positive dependence) and hence, it is appropriate to model both kind of dependencies (negative and positive)
between the surrogate endpoint and the final outcome. Many other copulas can also be used to model a variety of different
dependence structures, but this is out of the scope of this research.
2.3.2 Bivariate random effects meta-analysis with bivariate copulas (BRMA-BC)
BRMA-IB model assumes independence of the summarised events across arms and outcomes. However, in the context of
surrogate endpoints (or correlated binary outcomes) this assumption is fairly strong. At the within-study level, the summarised
events in each arm on the first and the second outcome are obtained from the same patients. Therefore, they are correlated. A
more rational modelling approach is to model the events on both outcomes jointly assuming some kind of association between
them. This can be achieved by using a copula representation with discrete (binomial) marginals, as copulas account for the
dependence between marginals and allow for modelling various dependence structures, providing a flexible representation of
the bivariate distribution. Therefore, a joint density made with copulas can be much more flexible compared to the bivariate
normal distribution which only allows for normal marginals and linear dependence structure.
At the within-study level, we assume that the summarised events in each arm on both outcomes follow bivariate distributions
ℎ(푝1푖, 푝2푖, 푁푖, 휃푖) with binomial marginal distributions. The parameters 푝1퐴푖, 푝2퐴푖, 푝1퐵푖, 푝2퐵푖 denote the true probabilities of the
summarised events in each arm on the first and the second outcome,푁퐴푖 and푁퐵푖 are the number of patients in the control arm
퐴 and experimental arm 퐵 in trial 푖. Additionally, 휃퐴푖, 휃퐵푖 are the dependence parameters in each arm respectively and they are
known when IPD are available.(
푟1퐴푖
푟2퐴푖
)
∼ ℎ(푝1퐴푖, 푝2퐴푖, 푁퐴푖, 휃퐴푖)
(
푟1퐵푖
푟2퐵푖
)
∼ ℎ(푝1퐵푖, 푝2퐵푖, 푁퐵푖, 휃퐵푖)
푔(푝1퐴푖) = 휇1푖, 푔(푝1퐵푖) = 휇1푖 + 훿1푖 푔(푝2퐴푖) = 휇2푖, 푔(푝2퐵푖) = 휇2푖 + 훿2푖(
훿1푖
훿2푖
)
∼ 푁
((
푑1
푑2
)
,
(
휏21 휏1휏2휌푏
휏1휏2푖휌푏 휏22
))
where
ℎ(푟1퐴푖, 푟2퐴푖|푝1퐴푖, 푝2퐴푖, 푁퐴푖, 휃퐴푖) = 퐶(퐹1(푟1퐴푖), 퐹2(푟2퐴푖), 휃퐴푖) − 퐶(퐹1(푟1퐴푖 − 1), 퐹2(푟2퐴푖), 휃퐴푖)
− 퐶(퐹1(푟1퐴푖), 퐹2(푟2퐴푖 − 1), 휃퐴푖) + 퐶(퐹1(푟1퐴푖 − 1), 퐹2(푟2퐴푖 − 1), 휃퐴푖),
ℎ(푟1퐵푖, 푟2퐵푖|푝1퐵푖, 푝2퐵푖, 푁퐵푖, 휃퐵푖) = 퐶(퐹1(푟1퐵푖), 퐹2(푟2퐵푖), 휃퐵푖) − 퐶(퐹1(푟1퐵푖 − 1), 퐹2(푟2퐵푖), 휃퐵푖)
− 퐶(퐹1(푟1퐵푖), 퐹2(푟2퐵푖 − 1), 휃퐵푖) + 퐶(퐹1(푟1퐵푖 − 1), 퐹2(푟2퐵푖 − 1), 휃퐵푖)
퐹1(푟1퐴푖), 퐹2(푟2퐴푖) and 퐹1(푟1퐵푖), 퐹2(푟2퐵푖) are the CDFs of the binomial marginal distributions on the surrogate and the final
outcome and 퐶(⋅, ⋅) is the bivariate copula.
We assume that within-study dependencies are different across studies and hence each study has a different dependence
parameter. However, in cases where individual patient data are not available across all studies, we can relax this assumption
having the same dependence across them. In the absence of IPD, we can construct informative prior distributions combining
evidence from external sources such as observational studies. At the between-studies level, the model is exactly the same as
BRMA-IB. The true probabilities of events 푝1퐴푖, 푝2퐴푖, 푝1퐵푖, 푝2퐵푖 are transformed using a link function 푔(⋅) and the true treatment
effects on both outcomes are normally distributed. This model was implemented in the Bayesian framework assuming the same
prior distributions as BRMA-IB.
3 SIMULATION STUDY
The proposed methods make different assumptions at the within-study level. BRMA-IB assumes that the summarised number
of events across outcomes are independent and binomially distributed whereas, BRMA-BC models the summarised events on
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both outcomes jointly accounting for the dependence structure between them. We carried out a simulation study to assess the
performance of BRMA model and the two proposed methods and in particular to investigate the impact of the magnitude of
within-study association on the performance of the three models.
3.1 Simulation scenarios varying within-study association, proportions of responders, number of
participants
We simulated data under 18 scenarios generating 1000 replications for each of them. Across scenarios, Frank copula was used to
simulate correlated IPD (which is also the copula function we use to implement BRMA-BCmodel). To measure the effect of the
within-study association, we varied the strength of association by assuming weak, moderate and strong within-study associations
(see details in step 6 of the data generation below). To test the effect of the proportions of events on the performance of the
models, we also considered different baseline treatment effects. Baseline effects 휇1푖,2푖 were drawn from the bivariate normal
distribution (see details in step 3 of the data generation below). As the baseline effects are transformed on the 푙표푔푖푡 scale, setting
the mean baseline effects 휂1,2 = 0 correspond to 50% proportion of events in the control arm (as 푙표푔푖푡−1 ≈ 0.5), and similarly,
휂1,2 = 3 correspond to 95% proportion of events and 휂1,2 = 4 imply that there are around 98% of events in the first arm and on
both outcomes. Lastly, we considered two settings for study sizes. The study size in both arms of each study were drawn from
the following normal distribution: 푛퐴푖,퐵푖 ∼ 푁(푚, 5) where 푖 = 1, ..., 푁 and rounded off to the nearest integer. Setting 푚 = 300
and 푚 = 80 covers the typical sizes of phase 3 and phase 2 trials in CML.
The generation process is the following:
1. Set the number of studies to thirty (푁 = 30).
2. Simulate the heterogeneous arm sizes 푛푖 of each study 푖 from the following normal distribution (푛푖 ∼ 푁(푚, 5)) and then
round off to the nearest integer.
3. Simulate the baseline treatment effects 휇1푖, 휇2푖 from the following bivariate normal distribution (휇1푖, 휇2푖)푇 ∼
퐵푉 푁
((
휂1
휂2
)
,
(
푠21 푠1푠2휌
푠1푠2푖휌 푠22
))
, with 푠1 = 푠2 = 0.1 and 휌 = 0.8.
4. Simulate the true treatment effects from (훿1푖, 훿2푖)푇 ∼ 퐵푉 푁
((
푑1
푑2
)
,
(
휏21 휏1휏2휌푏
휏1휏2푖휌푏 휏22
))
, with 푑1 = 0.4, 푑2 = 0.2,
휏1 = 0.5, 휏2 = 0.5, 휌푏 = 0.8.
5. Calculate the proportions of events from 푝1퐴푖 = 푙표푔푖푡−1(휇1푖), 푝2퐴푖 = 푙표푔푖푡−1(휇2푖), 푝1퐵푖 = 푙표푔푖푡−1(휇1푖 + 훿1푖), 푝2퐵푖 =
푙표푔푖푡−1(휇2푖 + 훿2푖) in each arm across outcomes.
6. To simulate (weakly, moderately and highly) correlated binary IPD, we used a joint density (made with Frank copula) of
Bernoulli marginal distributions in both arms with dependence parameters 휃퐴 and 휃퐵 . For each set of proportions of events
(50%, 95%, 98%) we chose a different value of the dependence parameters to reflect low, moderate and high within-study
association. The dependence parameters 휃퐴 and 휃퐵 for all the simulated scenarios along with the approximate value of
corresponding Spearman’s correlation are presented in section A.5 of the supplementary material.
The dependence parameter of Frank copula 휃 was obtained by transforming the corresponding Spearman’s correlation
across scenarios.
7. Summarise the number of events in each arm and outcome by taking the sum of the binary responses.
This process gives us a dataset with correlated summarised events on the first and the second outcome in each arm, as well as,
the original correlated binary IPD.
We fitted BRMAmodel, BRMA-IBmodel and BRMA-BCmodel with Frank copula to the generated data. As it was explained
in Sections 2.1, 2.3.2, BRMA and BRMA-BC methods take into account the within-study associations. When IPD are available
these parameters, the within-study correlation and the dependence parameter, can be estimated. To obtain the within-study cor-
relations for BRMA and the dependence parameters of BRMA-BCmodel, bootstrapping methods were used (see supplementary
material section A.3). The dependence parameters between the summary data had to be estimated as is it different than the one
use in the data generation process. This is because a Frank copula with Bernoulli marginals was used to generate IPD and a
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copula with Binomial marginals is used to model summary binomial data. BRMA-BC models binomial data in each arm at the
within-study level on both outcomes jointly using Frank copula with Binomial marginal distributions. However, the dependence
parameter of its copula is not the same as the one from the generation process since the marginal distributions are different.
To evaluate which method estimates better the relationship between the surrogate endpoint and the final outcome and derives
better estimates of true treatment effects, we stored the following: median between study correlation 휌푏; its 95% credible interval
(CrI); coverage of 휌푏 across 95%CrIs; average bias of 휌푏; coverage, average bias and RMSE for the between-studies heterogeneity
parameters 휏1 and 휏2, the mean treatment effects 푑1 and 푑2, and the true effects 훿1푖 and 훿2푖.
3.2 Results
The results of the simulation study are presented in Figures 1, 2, 3 and 4 covering all the scenarios. They present mean bias,
coverage across replications and root mean square error (RMSE) for the following estimates: between study correlation estimate
휌̂푏 (Fig. 1), between-studies heterogeneity estimate on the second outcome 휏̂2 (Fig. 2), the mean treatment effect estimate on the
second outcome 푑̂2 (Fig. 3) and the true treatment effect estimates on the second outcome 훿̂2푖 (Fig. 4).
3.2.1 Between-study correlation 휌푏
The between study correlation is the main parameter of interest in this paper as it quantifies the study level association between
the treatment effects on the surrogate endpoint and the final outcome. Figure 1 shows the performance measures for the estimate
of between-study correlation 휌̂푏. It can be seen that when the mean true baseline effects on the first 휂1 and the second outcome 휂2
were 0 (left hand side (LHS) plots), BRMA and BRMA-BCmodels performed very similarly in terms of their average accuracy,
coverage and RMSEs regardless of the sample size. As they both take into account the within-study association, there was no
difference in their performance across the different strengths of within-study associations. On the other hand, when within-study
association was moderate or strong, BRMA-IB was on average the least accurate method resulting also in slightly higher RMSEs
and under-coverage compared to the other two methods. Concerning the effect of study sample size, the smaller was the sample
size the higher were the average biases and RMSEs were across all methods.
When the proportions of events were approximately 95% (middle plots), BRMA-BC and BRMA-IB methods outperformed
BRMA model across all scenarios regardless of the sample size. BRMA model underestimated significantly 휌푏 in particular
when the arm sample size was small (푁 = 80) resulting in on average the lowest accuracy of the estimates and highest RMSEs.
Additionally, in this set of scenarios (middle plots), BRMA-BC was more accurate compared to BRMA-IB when the within-
study association was moderate or strong resulting in coverages closer to 95%. On the other hand the RMSEs of BRMA-BC
were higher than RMSEs of BRMA-IB. This implies that despite BRMA-BC gave on average less biased estimates, the variance
of the estimates was larger compared to BRMA-IB. The estimate of the between study correlation of BRMA-IB was upward
biased when푁 = 300 and some under-coverage was also observed when the within-study association was strong.
In the remaining sets of scenarios (right hand side (RHS) plots), BRMA-IB was the best method in the majority of scenarios in
terms of average accuracy and RMSE of the estimate of the between-study correlation. Only when the within-study association
was strong and the sample size 푁 = 300, it was slightly more biased than BRMA-BC. The other two methods substantially
underestimated the between study association a lot, however, BRMA-BC was more accurate and its coverage was closer to
95% compared to BRMA across all these scenarios. BRMA model failed to estimate 휌푏 as the assumption of normality was
unreasonable in these scenarios respectively.
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FIGURE 1 Performance of 휌̂푏 across 18 scenarios
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3.2.2 Between-study variance 휏2
To have a better understanding of the behaviour of the between-study covariance matrix we also monitored the between-study
heterogeneity parameters 휏1, 휏2. In this section, we report only the performance of the estimate of 휏2 as 휏̂1 performed in a very
similar way. Figure 2 presents the performance of 휏̂2 in terms of average bias, coverage and RMSEs. When the proportions of
events were close to 0.5 (LHS plots) all methods were on average accurate, with coverages very close to 95% and small RMSEs
regardless of sample size. Only when within-study association was high, BRMA-IB slightly overestimated 휏2 resulting in higher
on average bias compared to BRMA-BC and BRMA.
When the proportions of events were approximately 0.95 (middle plots), BRMAmodel underestimated 휏2 across all strengths
of within-study association regardless of the sample size. When 푁 = 300, the higher was the strength of the within-study
association the more downward biased were the estimates from BRMA. On the other hand, when the sample size was small
(푁 = 80) the estimates of 휏2 were equally biased across all the strengths of the within-study association. This indicates that
BRMA is performs worse when the sample size is small and the proportion of events is close to one or zero. Note that under-
or overestimation of the heterogeneity parameters will affect the estimates of the between-studies correlation, which explains
why 휌푏 obtained from BRMA was underestimated. BRMA-IB overestimated the heterogeneity parameter 휏2 mainly when the
within-study association was moderate or strong and in particular when the sample size was smaller,푁 = 80. This makes clear
the upward biased results of 휌푏 from this method. Furthermore, Some under-coverage was also observed from BRMA model
when the within-study association was moderate or strong regardless the sample size and from BRMA-IB when the within-
study association was moderate or strong and the sample size 푁 = 80. BRMA-BC was the only accurate method in this set of
scenarios resulting also in smaller RMSEs and acceptable coverages for 휏̂2.
In the final set of scenarios (RHS plots), BRMA-BCwas again superior compared to BRMA and BRMA-IBmodels. It yielded
the most robust results achieving acceptable coverages when푁 = 300, on average very accurate estimates and relatively small
RMSEs. In contrast to BRMA-BC, BRMA and BRMA-IB models performed poorly having similar patterns as in the previous
set of scenarios. In this case, they had even more biased estimates and larger RMSEs compared to the previous set of scenarios.
Concerning the effect of within-study association when 푁 = 300, the stronger is the association, BRMA model is expected to
underestimate the heterogeneity parameters, whereas BRMA-IB to overestimate them. These findings show that BRMA model
is completely inappropriate method in such scenarios. Furthermore, this indicates that BRMA-IB estimated 휌푏 unrealistically
accurately, in scenarios where it was not possible due to the small sample size and the extremely high proportion of events,
since it substantially overestimated the heterogeneity parameters. BRMA-IB was also the most sensitive method to the effect of
sample size as its RMSEs were significantly larger compared to any other method when the sample size was small (푁 = 80)
and its biases were much larger compared to the set of scenarios with푁 = 300
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FIGURE 2 Performance of 휏̂2 across 18 scenarios
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3.2.3 True treatment effects 훿2푖 and mean treatment effects 푑2
In this section we present the results from the pooled estimate 푑2 across all the models and scenarios, as well as, the true treatment
effects 훿2푖. In the general meta-analytic framework the mean treatment effects are the main parameters of interest. However, in
the context surrogate endpoints 훿2푖 correspond to the true treatment effects on the final outcome. These are the effects we aim
to predict using the true treatment effect of a surrogate endpoint. Therefore, it is crucial to assess and compare the performance
of the estimates of 훿2푖 from BRMA model and the proposed methods.
First we discuss the performance of the pooled estimate 푑̂2. Figure 3 presents the performance of 푑̂2 by monitoring the average
bias, the coverage and RMSEs across the 18 scenarios. We decided to present results from 푑̂2 and 훿̂2푖, as the estimates on the the
first outcome performed almost identical. When the proportions of events were approximately 0.5 (LHS plots) and the sample
size 푁 = 300 all methods performed well and in a very similar way. BRMA-IB was the most sensitive to the effect of sample
size resulting in higher biases and reduced coverages compared to BRMA and BRMA-BC when the sample size was small and
the within-study association moderate or strong.
When then the proportions of events were approximately 95% (middle plots) BRMA gives downward biased estimates of
푑2, reduced coverages and for scenarios with 푁 = 300 higher RMSEs compared to the proposed methods, indicating that
the assumption of normality was not reasonable. Another interesting finding was the effect of within-study association on the
estimates of 푑2. The stronger was the within-study association the more downward biased were the estimates from BRMA.
On the other hand, BRMA-BC was quite accurate across all the scenarios for 푁 = 300 and having the lowest RMSEs across
scenarios for푁 = 80.
In the remaining scenarios (RHS plots) BRMA-BC and BRMA-IB performed very similarly. However, when the sample size
was small and the proportion of events high (휂1,2 = 4 and 푁 = 80) BRMA-IB performed poorly. The estimates from BRMA
model remained biased method across these scenarios, although it copes slightly better with the small sample size and the high
proportion of events compared to BRMA-IB.
Figure 4 presents the average bias, the coverage and RMSEs of 훿̂2푖 across the 18 scenarios. The main findings were very
similar to the analysis of 휏2 and 푑2. When the proportions of events 50% (LHS plots), BRMA model and BRMA-BC performed
well. BRMA-IB is slightly more biased when the within-study association was strong resulting in under-coverage and larger
RMSEs of the estimates of 훿2푖.
BRMA model was more biased compared to the other two methods when the proportions of events were 95% and 98%.
When the within-study association was weak or moderate, the estimates of the true treatment effect on the second outcome from
BRMA-IB and BRMA-BC performed similarly in terms of average accuracy, RMSE and coverage. BRMA-BC outperformed
BRMA-IB when the within-study association was moderate or strong resulting in lower RMSEs.
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FIGURE 3 Performance of 푑̂2 across 18 scenarios
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FIGURE 4 Performance of 훿̂2푖 across 18 scenarios
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3.3 Key findings
A short summary of the key findings from the simulation study is given below:
• The simulation study showed that the normal approximation fails for binary outcomes when the proportions of events
are close to one or zero. This confirms findings by Hamza et al.6 for the univariate case and extends their finding to the
bivariate cases. In our simulation study we focused on the performance of the parameters describing the between-studies
variability: the between-studies correlation 휌푏 and heterogeneity parameters 휏1, 휏2. When the proportions of events are
close to 0.5 (휂1,2 = 0), there is no clear difference between BRMAmodel and BRMA-BC as they performed very similarly
and sufficiently well. However, when the proportions of events are high, BRMA yielded poor coverages, large RMSEs
and biased estimates of 휌푏, 휏1,2 푑1,2 and 훿1푖,2푖. Therefore, BRMA model is not appropriate to estimate the study level
association for binary outcomes with very large probabilities of events.
• Another aim of the simulation study was to explore the impact of the within-study association on the estimation of the
between-studies variability across methods. BRMA-IB model was the most sensitive method by far. This model assumes
that events are independent and binomially distributed across outcomes. This assumption makes the model quite robust
when the proportions of events are high and the within-study association is small, but inappropriate when the within-study
association is moderate or strong. When the proportions of events were high, higher within-study association led to poorer
coverage and larger RMSEs. Overall, BRMA-IB is a reliable method only when within-study association is small. In any
other case it should be avoided as it overestimates the between study heterogeneity and gives estimates of true treatment
effect with higher RMSEs compared to BRMA-BC. This behaviour leads to unrealistically accurate and precise estimates
of 휌푏 in some scenarios where, study size is small and the proportions extremely high (small within-study variability).
• The simulation study also investigated the effect of sample size by having two sets of scenarios. Overall, smaller sample
size results in higher biases and larger RMSEs across all methods. BRMA-IB model was most sensitive to the effect
of sample size. Small sample and proportions of events close to one or zero make BRMA-IB model inappropriate for
modelling correlated binary outcomes. For instance, when 푁 = 80 and the proportions of events were 98%, BRMA-
IB performed worse than BRMA in terms of bias and RMSE of 휏̂2, 푑̂2 and 훿̂2푖 in this scenario. On the other hand when
sample size was large (푁 = 300), BRMAmodel yielded more biased estimates as the strength of within-study association
increased. We did not, however, observe the same behaviour when the sample size was small (푁 = 80). Overall, BRMA-
BC was less sensitive to the effect of sample size across all scenarios.
• BRMA-BC is the most appropriate method to investigate the study level association between treatment effects on two
binary outcomes. The model performed sufficiently well under any setting without over/underestimating the between-
studies variances. There were scenarios in the simulation study, where it failed to estimate 휌푏 as accurately and precisely as
BRMA-IB. This was due to the extremely high proportion of events. In practice, investigating between-studies association
between binomial endpoints with proportions of events close to one or zero will require sufficiently large sample size.
This will allow the model to estimate the between-studies correlation accurately and with good precision.
4 DATA EXAMPLE
CML is a myeloproliferative neoplasm of hematipoietic stem cells associated with a characteristic chromosomal translocation
called the Philadelphia chromosome. The main characteristic is that CML is regarded as a slow progressive disease12. Before
the molecular pathogenesis of the disease was well understood, the median survival was 6 years, with a predicted 5-year overall
survival (OS) of 47.2%13. However, the introduction of tyrosine kinase inhibitor (TKI)15 therapies has led to dramatically
improved long-term survival rates since 2001 resulting in high response rates of complete cytogenetic response (CCYR) at
12 months and very few events such as loss of response (e.g complete cytogenetic response, major molecular response etc.),
progression to accelerated phase (AP) or blast crisis (BC) and death from any cause. To illustrate the proposed methods and
compare them with BRMA model we identified 10 studies comparing first generation TKI therapies (e.g 400mg imatinib)
with second generation TKIs (e.g. dasatinib, nilotinib,busotinib) or different doses of first generation TKIs (600mg or 800mg
imatinib). We selected to evaluate the study level association between two binary outcomes, CCyR at 12 months and event-free
survival (EFS) at 24 months. We chose CCyR at 12 months as it has been extensively used in the literature as a gold standard
for a good measure of response and EFS at 24 months as it is very significant in view of the dismal prognosis of the patients
Papanikos ET AL 15
proceeding to advanced stages or losing response. Table 1 presents the summarised responses in the treatment and the control
arm on both outcomes along with the sample size per arm and outcome. To work with positive correlations we measured the
number of patients who were event-free at 24 months EFS.
TABLE 1 Summarised data in CML
Complete Cytogenetic Response Event-Free-Survival
Control arm Treatment arm Control arm Treatment arm
Study name Arm size Responses Arm size Responses Arm size Events Arm size Events
Cortes 201227 252 171 250 175 252 222 250 230
Kantarjian 201028 260 189 259 216 260 239 259 243
Radich 201229 61 42 70 59 123 117 123 118
Saglio 201030 243 184 236 219 283 267 281 276
Baccarani 200931 108 63 108 69 108 74 108 77
Preudhomme 201032 158 92 160 104 159 149 160 149
Hehlmann 201133 306 151 328 206 324 308 338 317
Cortes 201034 157 103 319 223 157 149 319 311
Deininger 201335 49 33 41 35 73 68 72 60
Wang 201536 133 107 134 104 133 125 134 124
4.1 Results
The aim of our analysis was to evaluate the study level surrogate relationship between the candidate endpoint (CCyR) at 12
months and the final outcome (EFS) at 24 months using the proposed methods and the BRMAmodel. As IPD were not available
from any of these studies, we were unable to estimate the dependence parameters of BRMA-BC and Pearson’s within-study
correlation of BRMA and instead we placed informative prior distributions on these parameters. To construct informative prior
distributions we used three cohort studies37,38,39. These studies measured the impact of achieving a CCyR at 12 months on longer
term outcomes by reporting rates of EFS for patients who did or did not achieve CCyR at 12 months. Having these rates we could
create pseudo IPD, and hence calculate the within-study association parameters with uncertainty by using a double bootstrap
method (see more details in the section A.4 of the supplementary material). Figure 5 shows the three probability densities
derived from the external evidence using the double bootstrap method. The first density corresponds to the Pearson’s within-
study correlation 휌푤 used to populate BRMA model and the other two are prior distributions for the dependence parameters 휃퐴
and 휃퐵 of BRMA-BC.
FIGURE 5Within-study associations
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We assumed the same prior knowledge for the within-study association parameters across all studies. The remaining param-
eters have the same prior distributions as in the simulation study. Figure 6 presents the posterior distributions from the
between-studies correlation parameter 휌푏 across models.
FIGURE 6 Posterior distributions of 휌푏 across models
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BRMA model yielded a posterior distribution of 휌푏 with significantly smaller median (0.37), while the scale and the shape
of the posterior distribution was flatter compared to the posterior distribution of BRMA-IB and BRMA-BC. In the simulation
study BRMA underestimated the study level association in similar sets of scenarios, hence we can infer that BRMA model fails
to capture part of the between-studies association due to high proportions of events across studies on EFS. On the other hand, the
shape of the posterior distributions from BRMA-BC and BRMA-IB were very similar. The median of the posterior distribution
of BRMA-IB was 0.60 and the median of BRMA-BC was 0.52. This can potentially imply that the estimate from BRMA-IB
was slightly biased, as in the simulation study the estimates of 휌푏 from BRMA-IB were upward biased in most of the scenarios.
To investigate further the performance of the models we monitored the between-study heterogeneity parameters 휏1 and 휏2 as
well as the pooled treatment effects 푑1 and 푑2. Table 2 presents the results of the between-studies estimates.
TABLE 2 Between-studies estimates across models
Models BRMA BRMA-BC BRMA-IB
Measures Mean(Median) 95% CrI Median(Mean) 95% CrI Median(Mean) 95% CrI
Parameters
휌푏 0.23(0.37) (-0.93, 0.97) 0.35(0.52) (-0.87, 0.97) 0.44(0.60) (-0.84, 0.98)
휏1 0.40(0.38) ( 0.11, 0.83) 0.45(0.42) ( 0.17, 0.90) 0.46(0.43) ( 0.14, 0.95)
휏2 0.25(0.21) ( 0.01, 0.72) 0.28(0.24) ( 0.01, 0.81) 0.33(0.30) ( 0.01, 0.91)
푑1 0.45(0.45) ( 0.14, 0.78) 0.48(0.48) ( 0.15, 0.82) 0.49(0.49) ( 0.12, 0.83)
푑2 0.27(0.27) (-0.05, 0.61) 0.30(0.29) (-0.02, 0.63) 0.30(0.29) (-0.04, 0.70)
BRMA-BC and BRMA-IB yielded higher values for the estimates of between-studies heterogeneity parameters compared
to BRMA model. This agrees with the findings of the simulation study, as when the response rates were high, BRMA model
underestimated the between-study heterogeneity. On the other hand, since BRMA-IB ignored the within-study association it
yielded more uncertainty around the estimates of pooled effects. This is in agreement with the findings by Riley et al.9. They
proved the importance of taking into account the within-study correlation when BRMA model is used. When BRMA model
ignores the within-study association it also yields pooled estimates with larger uncertainty. BRMA-BC resulted in increased
uncertainty around the pooled estimate 푑1 compared to BRMAmodel. This potentially is related to the smaller values of between-
studies variance or to the accuracy of the bootstrap method. Overall, the study level association was suboptimal as the credible
intervals of 휌푏 were very wide, spanning almost from -1 to 1. This implies that CCyR at 12 months is not valid surrogate endpoint
for EFS at 24 months. This is possibly due to the lack of evidence of treatment effect on EFS at 24 months, as many studies
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have previously reported27,28,30. It indicates that long-term outcomes should be used for the validation of CCyR at 12 months.
However, this is not feasible, as very few studies report EFS at 5 or 7 years.
5 DISCUSSION
We have developed two methods for bivariate random effects meta-analysis of binomial data which allow for modelling the
within-study variability using exact binomial likelihoods. The proposed methods offer a robust framework for meta-analysis
of binary outcomes avoiding the use of an unreliable approximation of normality for log odds ratios. In this paper, we used
these methods for the evaluation of study level surrogate relationship between treatment effects on binary outcomes for novel
targeted therapies, where the increased effectiveness of these treatments often leads to high number of responses and reduced
number of events. In our case study of highly effective TKI therapies in CML, the validation of CCyR as a surrogate endpoint
to EFS (or OS) has been extremely challenging, due to such high response rates and very few events recorded over the duration
of each trial. Standard meta-analytic methods, such as BRMA model, can model the observed treatment effects at the within-
study level using a bivariate normal distribution of log odds ratios. Although this approach takes into account the within-study
association, the assumption of normality is often unreasonable leading to biased results. BRMA-IB model is a more restrictive
method of the two we propose. It models the within-study variability using binomial likelihoods, however, these likelihoods
are independent therefore the method does not take into account the within-study association. BRMA-BC is more flexible as it
models the summarised events on the surrogate endpoint and the final outcome in each arm jointly. This is more appropriate as
the number of events on both outcomes are obtained from the same patients.
BRMA-IBmodel performs well when the proportions of events are high and the within-study association is weak, givingmore
accurate estimates and smaller RMSEs compared to BRMA model. However, in scenarios where the within-study association
is strong or moderate the model fails to estimate well the between-study heterogeneity, giving upward biased estimates of the
between-studies correlations and standard deviations; 휌푏 and 휏1,2, higher RMSEs and unreasonably low coverage probabilities.
In the extreme set of scenarios (proportions of events ≈ 0.98), the method estimated 휌푏 unrealistically well. This occurred due
to the heterogeneity parameters and the true treatment effects being substantially overestimated by this model.
BRMA-BC is the most robust model to quantify the study level association as it takes into account within-study associations
whilst avoiding the use of the assumption of normality at the within-study level. In particular the model does not over/underes-
timate the heterogeneity parameters 휏1,2. This lead to more reasonable estimates of the between-study correlation 휌푏. Overall,
across the 18 scenarios of the simulation study, BRMA-BC model was superior to BRMA model. However, there were some
extreme scenarios where it failed to yield as accurate estimates of 휌푏 as BRMA-IB model. For instance, when the proportions of
events were ≈ 0.98, BRMA-BC model yielded on average downward biased estimates of 휌푏 regardless of sample size. However,
this was due to small sample and the very small number of non-events which makes the estimation of 휌푏 extremely difficult.
Therefore, when the proportions of events are extremely high, we need very large sample sizes in order to estimate 휌푏 accurately
and precisely.
In the illustrative example, all methods found the study level association between CCyR at 12 months and EFS at 24 months
suboptimal as the 95% CrI of 휌푏 was extremely wide, spanning almost from -1 to 1. However, BRMA-BC model gave larger
estimates of the median between-study correlation 휌푏 and the median between-studies standard deviations 휏1, 휏2 compared to
BRMA model. Overall, the posterior distribution of 휌푏 from BRMA model was much flatter compared to the other two models.
This behaviour is in agreement with the findings from the simulation study. Additionally, BRMA-BC model gave slightly better
predictions in terms of uncertainty and errors.
Although BRMA-BC model provide robust results in a variety of scenarios, potential limitations should always be kept
in mind. First, in order to perform Bayesian inference, we had to run Hamiltonian Monte Carlo (HMC) with Rstan40 . The
model was very sensitive to initial values, making difficult the initiation of the HMC process. We solved this problem by fitting
BRMA-IB or BRMA models first and then we used their estimates as initial values for BRMA-BC model.
A limitation of the illustrative example was the lack of IPD. We informed the prior distributions of within-study association
parameters using 3 cohort studies. We constructed binary pseudo IPD and hence calculated the within-study association between
the number responses on the surrogate endpoint and the within-study association between the number of events on the final
outcome by using a double bootstrap method to account for uncertainty. Furthermore, the definition of EFS varies across these
studies. Some studies present it as PFS, some others include more types of events in their definition than others. However, by
excluding a small studies where EFS was defined slighlty differently did not affect the results and our inferences.
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BRMA-BC can be extended in a number of ways. For instance, it can be extended by using also a copula at the between-
study level in a similar way as in Nikolopoulos et al.41. This will allow to model the study level association on the true scale
(proportions of events) with beta marginal distributions avoiding the logit transformation. Furthermore, taking advantage of the
setting proposed by Bujkiewicz et al42, BRMA-BC can be extended to allow for modelling multiple surrogate endpoints (or the
same surrogate endpoint but reported at multiple time points) via a vine-copula. Furthermore, we used only Frank copula to
construct the joint densities at the within-study level of BRMA-BCmodel, but other copulas with various dependence structures
can be used. However, this is out of the scope of this paper. We performed a short sensitivity analysis fitting BRMA-BC with
Gumbel copula and the performance of the model was very similar. In general, when data are sparse (such as in meta-analysis
of aggregate data) it is very challenging to capture the exact dependence structure, and therefore different copula functions have
small impact on the performance of the model in such cases.
In summarywe developed Bayesian hierarchical meta-analytic methods to perform bivariatemeta-analysis of binary outcomes
and particularly, to quantify the study level surrogate relationship. In our view, BRMA-BC is a preferred model for modelling
binary outcomes in the context of surrogate endpoints, as well as, in the general meta-analytic framework. Themodel can improve
the process of the validation of surrogate endpoints in the era of personalised medicine where the increased effectiveness of
targeted treatments often leads to high number of responses and reduces the number of events.
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